Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Mini Oral session: Supportive and palliative care

1558MO - Dissecting sexual health after breast cancer (BC) by longitudinal assessment of patient reported outcomes


10 Sep 2022


Mini Oral session: Supportive and palliative care


Patient Education and Advocacy;  Supportive Care and Symptom Management;  Survivorship

Tumour Site

Breast Cancer


Maria Alice Franzoi


Annals of Oncology (2022) 33 (suppl_7): S713-S742. 10.1016/annonc/annonc1075


M.A. Franzoi1, M. Aupomerol2, J. Havas1, H. Hang1, A. Di Meglio1, M. Lambertini3, C. Massarotti4, C. Coutant5, O. Tredan6, F. Joly Lobbedez7, P.H. Cottu8, D. Soldato3, M. Mouret9, C. Tarpin10, A. Arnaud11, L. Fasse2, S. EVERHARD12, A. Martin12, B. Pistilli2, I. Vaz Luis1

Author affiliations

  • 1 Inserm Unit U 981, Institut Gustave Roussy, 94805 - Villejuif, Cedex/FR
  • 2 Breast Cancer Group, Institut Gustave Roussy, 94805 - Villejuif/FR
  • 3 Clinica Di Oncologia Medica, IRCCS Ospedale Policlinico San Martino, 16132 - Genova/IT
  • 4 Gynecology, IRCCS Ospedale Policlinico San Martino, 16132 - Genova/IT
  • 5 Surgical Oncology, Centre Georges Francois Leclerc, 21000 - Dijon/FR
  • 6 Centre Léon Bérard, Medical Oncology, 69008 - Lyon/FR
  • 7 Medical Oncology Department, Centre Francois Baclesse, 14076 - Caen, Cedex/FR
  • 8 Department Of Medical Oncology, Institut Curie, 75005 - Paris/FR
  • 9 Medical Oncology Department, Centre Jean PERRIN, 63011 - Clermont-Ferrand, Cedex /FR
  • 10 Medical Oncology Department, IPC - Institut Paoli-Calmettes, 13273 - Marseille, Cedex /FR
  • 11 Radiotherapy Departement, Institut Sainte-Catherine, 84918 - Avignon/FR
  • 12 Research, UNICANCER, 75654 - Paris/FR


Login to access the resources on OncologyPRO.

Abstract 1558MO


Sexual concerns are a major unaddressed need among survivors of BC with significant negative effect on quality of life.


Patients (pts) with stage I-III BC were prospectively included from CANTO providing data at diagnosis (T0), 1 (T1), and 2 (T2) years afterwards. Study outcomes were poor body image (score ≤91/100), poor sexual functioning (≤16/100) poor sexual enjoyment (≤66/100) and sexual inactivity (item 45=1) at T2 assessed by EORTCQLQ-B23 (Karsten EJC 2022). Multivariable logistic regression models assessed associations with sexual concerns adjusting for age, sociodemographic, tumor, treatment and clinical characteristics.


Analysis included 7,895 pts. At T0, 32.1% of pts already presented poor body image, 39.3% poor sexual functioning, 29.1% poor sexual enjoyment, and 39% were sexually inactive. The proportion of pts reporting sexual concerns increased over time: 52.6% and 38.1% reported poor body image and sexual enjoyment at T2, respectively. Factors consistently associated with sexual concerns at T2 included: presence of the same concern at T0, endocrine therapy (ET) use and emotional distress. Gynecologist consultation was associated with lower likelihood of reporting sexual concerns at T2 – Table. Dimension specific associations with poor body image included higher education (OR 1.4 [95%CI 1.1-1.8), prior smoking (1.3[1.1-1.6]), mastectomy (2[1.6-2.4]), receipt of chemotherapy (1.5[1.3-1.8]), fatigue (1.5[1.3-1.8]) and pain (1.3[1.0-1.5]) reported at T1, whereas poor sexual enjoyment was associated with lower education (1.6[1.0- 2.6]). Table: 1558MO

Associations with sexual concerns at T2: OR; 95% CI

Variable Body image Sex functioning Sex enjoyment Sex inactivity
Concern T0 vs no 3.40; 2.93-3.95 10.83; 9.17-12.76 4.19; 3.37-5.21 10.50; 8.94-12.34
Age (<40 vs > 65y) - 7.63; 4.90-12.04 2.46; 1.54-3.93 8.26; 5.31-12.80
Income (<1500 vs ≥3000) - 1.49; 1.10-2.01 - 1.55; 1.15-2.07
BMI ≥ 25 vs <25 1.32; 1.11-1.59 1.39; 1.12-1.74 - 1.35; 1.09-1.68
ET vs no 1.24; 1.04-1.48 1.33; 1.06-1.66 1.49; 1.13-1.97 1.34; 1.08-1.67
Depression* vs no 1.95; 1.59-2.40 1.33; 1.05-1.68 1.75; 1.27-2.41 1.39; 1.10-1.74
Vaginal dryness* vs no 1.19; 1.04-1.37 - 1.74; 1.41-2.14 0.74; 0.63-0.80
Gynecologist* vs no - 0.70; 0.59-0.84 0.74; 0.60-0.92 0.73; 0.61- 0.87

*at T1;


Sexual concerns seem to substantially increase from BC to the after treatment period reaching more than half of pts 2y after diagnosis. This study identified a number of factors associated with sexual concerns. Communication on sexual health must exist across the whole cancer care continuum so that pts can be identified and receive proper multidisciplinary counselling.

Clinical trial identification


Editorial acknowledgement

Legal entity responsible for the study



National Research Agency (grant ANR-10-COHO-0004 for the Cancer Toxicity study); Gustave Roussy Foundation (INTERVAL).


M. Lambertini: Financial Interests, Personal, Advisory Board: Roche, AstraZeneca, Lilly, Novartis, Exact Sciences, MSD, Seagen, Gilead; Financial Interests, Personal, Invited Speaker: Pfizer, Takeda, Sandoz, Ipsen, Libbs, Knight. F. Joly Lobbedez: Financial Interests, Personal, Advisory Board: GSK, AstraZeneca, MSD, Janssen, ipsen, BMS, Bayer, Esai; Financial Interests, Personal, Invited Speaker: GSK, AstraZeneca, MSD, Janssen, Ipsen, Amgen, Astellas; Financial Interests, Institutional, Invited Speaker: GSK, AstraZeneca; Financial Interests, Institutional, Research Grant: BMS; Travel: MSD, GSK. B. Pistilli: Financial Interests, Personal, Advisory Board: Puma, Pierre-Faber, Novartis, Myriad Genetics, AstraZeneca, Daiichi/Sankyo; Financial Interests, Institutional, Research Grant: Pfizer, Puma Biotechnology, Merus, Daiichi/Sankyo. I.V. Luis: Financial Interests, Institutional, Invited Speaker: Amgen, AstraZeneca, Pfizer/Edimark, Novartis. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.